Key result
FoxO1 S284A mutation fails to prevent pressure overload-induced LVEF reduction vs wild-type mice.
Absolute Event Rate: 40% vs 38%
p-value: p=0.70
GSK-3b-induced phosphorylation of FoxO1 at S284 is protective against pathological hypertrophy and cardiac dysfunction during pressure overload.
Introduction: Glycogen synthase kinase-3β (GSK3β) is inactivated by phosphorylation at serine-9 (S9). Pressure overload (PO) induces phosphorylation of GSK3β at S9, whereas cardiac dysfunction and hypertrophy are attenuated in GSK3β-S9A knock-in (KI) mice. Thus, S9 phosphorylation of GSK3β mediates pathological hypertrophy. Forkhead box O1 (FoxO1) promotes cardiomyocyte survival by upregulating antioxidants in a context-dependent manner. We hypothesize that GSK3β phosphorylates FoxO1, thereby protecting the heart during PO. Methods and results: Co-immunoprecipitation assays demonstrated that GSK3β interacts with FoxO1. Mass spectrometry analysis showed that GSK-3b phosphorylates FoxO1 at serine-284 (S284). To examine the role of FoxO1 phosphorylation at S284, FoxO1 (S284A)-KI mice were generated. Baseline left ventricular ejection fraction (LVEF) was lower in FoxO1 (S284A)-KI mice than in wild-type (WT) mice (47 ± 5.2% vs. 52 ± 1.6%, p = 0.077, N = 5) at 6 weeks of age. The heart weight, normalized to tibial length, was significantly greater in FoxO1 (S284A)-KI mice than in WT mice (131 ± 15 mg/mm vs. 101 ± 7.8 mg/mm, p = 0.0048, N = 5). In addition, the gene expression level of catalase was significantly reduced in FoxO1 (S284A)-KI mice compared to in WT mice (p = 0.04). These results suggest that phosphorylation of FoxO1 at S284 promotes pathological hypertrophy through oxidative stress. Four weeks of transverse aortic constriction (TAC) significantly reduced LVEF in both WT and S284A-KI mice compared to that in WT-sham (53 ± 1.2%, both p < 0.01, N > 5). However, LVEF in WT mice after TAC was not significantly different from that in S284A-KI mice after sham and TAC, suggesting that TAC and FoxO1 (S284)-KI do not have additive effects upon cardiac dysfunction (LVEF in S284A-sham, WT-TAC and S284A-TAC: 42 ± 3.6% vs. 38 ± 8.9% vs. 40 ± 5.0, p = 0.70, N > 5). These results indicate that TAC-induced cardiac dysfunction is mediated through FoxO1 phosphorylation at S284. Conclusions: GSK-3b-induced phosphorylation of FoxO1 at S284 is protective in the heart, whereas TAC induces pathological hypertrophy by inhibiting S284 phosphorylation of FoxO1.
No takes yet. Share an insight, caveat, or question.
Takada et al. (2025) studied Cardiac dysfunction and pathological hypertrophy. FoxO1 (S284A) knock-in mutation and transverse aortic constriction (TAC) vs. Wild-type mice and sham operation was evaluated on Left ventricular ejection fraction (LVEF) after TAC (p=0.70). Transverse aortic constriction reduced LVEF similarly in wild-type and FoxO1 (S284A)-KI mice (38% vs 40%, p=0.70), indicating TAC-induced dysfunction is mediated through FoxO1 phosphorylation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: